Extracellular tumor DNA in plasma and overall survival in breast cancer patients
- PMID: 16607614
- DOI: 10.1002/gcc.20334
Extracellular tumor DNA in plasma and overall survival in breast cancer patients
Abstract
In this study, we examined whether free DNA extracted from the plasma of breast cancer patients, characterized as tumor DNA, could predict the overall survival (OS) of breast cancer patients. In total, 147 patients and 35 healthy controls were studied. Plasma DNA was assessed in the same way as tumor DNA, following identification of similar alterations in polymorphic markers and TP53 gene mutations. Although OS was the main focus of this study, recurrence and disease-free survival (DFS) were also analyzed. In 61 of the 142 patients, with an average 58 months of follow-up, a similar molecular signature in tumor and plasma DNA was detected. OS was 71% (95% CI, 61%-81%), and distribution as regards tumor plasma DNA was 59% (95% CI, 45%-73%) for positive cases and 83% (95% CI, 73%-93%) for negative cases (P = 0.01). Univariate analysis revealed a predictive value for tumor plasma DNA (P = 0.018) hazard ratio (HR) 2.5 (95% CI, 1.2-5.3), while multivariate analysis did not (P = 0.3), HR 1.6 (95% CI, 0.6-4.4). DFS was 37% (95% CI, 19%-55%) for positive patients and 75% (95% CI, 57%-93%) for negative patients (P = 0.005). Among the 35 recurrences observed, 25 were positive for tumor plasma DNA and 10 were negative, (P < 0.001). These results indicate that tumor plasma DNA at diagnosis can serve as a prognostic marker of the OS of breast cancer patients.
(c) 2006 Wiley-Liss, Inc.
Similar articles
-
Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival.Clin Cancer Res. 2002 Dec;8(12):3761-6. Clin Cancer Res. 2002. PMID: 12473587
-
p53 mutation in plasma DNA and its prognostic value in breast cancer patients.Clin Cancer Res. 2001 Aug;7(8):2222-7. Clin Cancer Res. 2001. Retraction in: Clin Cancer Res. 2002 Sep;8(9):3027. PMID: 11489795 Retracted.
-
Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations.Cancer Res. 1999 Jul 1;59(13):3251-6. Cancer Res. 1999. PMID: 10397273
-
259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.Breast Cancer Res Treat. 2008 Jun;109(3):405-16. doi: 10.1007/s10549-007-9668-7. Epub 2007 Aug 9. Breast Cancer Res Treat. 2008. PMID: 17687650 Review.
-
Circulating DNA in plasma or serum.Medicina (B Aires). 2000;60(5 Pt 2):699-702. Medicina (B Aires). 2000. PMID: 11188885 Review.
Cited by
-
The plasma DNA concentration as a potential breast cancer screening marker.Indian J Clin Biochem. 2015 Jan;30(1):55-8. doi: 10.1007/s12291-013-0407-z. Epub 2013 Nov 22. Indian J Clin Biochem. 2015. PMID: 25646041 Free PMC article.
-
Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology.Onco Targets Ther. 2013 Jul 8;6:819-32. doi: 10.2147/OTT.S44668. Print 2013. Onco Targets Ther. 2013. PMID: 23874104 Free PMC article.
-
Extracellular plasma RNA from colon cancer patients is confined in a vesicle-like structure and is mRNA-enriched.RNA. 2008 Jul;14(7):1424-32. doi: 10.1261/rna.755908. Epub 2008 May 2. RNA. 2008. PMID: 18456845 Free PMC article.
-
Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications.PLoS One. 2009 Dec 15;4(12):e8173. doi: 10.1371/journal.pone.0008173. PLoS One. 2009. PMID: 20016842 Free PMC article.
-
The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis.Medicine (Baltimore). 2018 Mar;97(13):e0197. doi: 10.1097/MD.0000000000010197. Medicine (Baltimore). 2018. PMID: 29595655 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous